Fibroblast growth factor receptor 1 (FGFR1) amplification has been identified in 10-20% of patients with squamous nonsmall-cell lung cancer. Preclinical models showed promising activity of specific FGFR inhibitors, but early clinical trials showed that only a small fraction of patients with FGFR1-amplified lung cancer responded to FGFR inhibitors. These unsatisfactory results were partly explained by heterogeneous amplicons around the 8p11 genomic region, leading to falsepositive amplification results. Furthermore, discrepancies in the gene amplification and protein expression of FGFR1 were also reported. In this study, we identified the roles of alternative receptor tyrosine kinases (RTKs) in FGFR1-amplified lung cancer. These alternative RTKs dominantly activate phosphoinositide 3-kinase-AKT signaling and also mitigate sustained inhibition of mitogen-activated protein kinase signaling by FGFR inhibitors. The rebound activation of extracellular signalregulated kinase phosphorylation was associated with sensitivity to the drugs. Combinatorial inhibition of alternative RTKs and FGFR1 was required to suppress both AKT and extracellular signal-regulated kinase phosphorylation and to induce key pro-apoptotic proteins BIM and p53 upregulated modulator of apoptosis (PUMA). Furthermore, even in FGFR inhibitor-sensitive NCI-H1581 lung cancer cells, MET-expressing clones were already detectable at a very low frequency before resistance induction. Selection of these pre-existing subclones resulted in FGFR inhibitor resistance because of the activation of AKT and extracellular signal-regulated kinase by MET signaling that was mediated by GRB2 associated binding protein 1 (GAB1). These results suggest that incomplete suppression of key survival signals led to intrinsic and acquired resistance to FGFR inhibitors. Our results may help explain the low clinical response rates to FGFR inhibitors in FGFR1-amplified lung cancer.
Introduction
Lung cancer is the leading cause of cancer death in the USA and Japan. The discovery of driver mutations in subsets of nonsmall-cell lung cancer has transformed the treatment paradigm of this disease (1, 2) . FGFR1 amplification has been identified in 10-20% of patients with squamous non-small-cell lung cancer (3) (4) (5) (6) . Preclinical studies suggested that FGFR1 amplification confers FGFR signaling dependence in cancer cells, leading to the development of several tyrosine kinase inhibitors (TKIs) and antibodies against FGFR1 (3, 4, 7) . However, early clinical trials showed that only a small fraction of these patients responded to FGFR inhibitors, in contrast to the promising results in patients harboring activating mutations or translocations of FGFR family genes (8) (9) (10) (11) .
These results raise the possibility that gene amplification is insufficient for patient stratification. We and others have shown that both amplification and increased protein expression are required to induce FGFR inhibitor sensitivity in FGFR1-amplified lung cancer cell lines (12, 13) . Furthermore, the prevalence of FGFR1 amplification is much lower when assessed by next-generation sequencing than that when assessed by FISH because of heterogeneous amplicons around the 8p11 genomic region (6, 14) . These results suggest that the number of patients with FGFR1-dependent lung cancer confirmed by both gene and protein expression is much lower than expected; however, it is still unclear whether FGFR1 is a clinically targetable oncogene in these patients.
Activated FGFR1 recruits the fibroblast growth factor receptor substrate 2 (FRS2) adaptor protein to the juxtamembrane region of FGFR1. The FGFR1-FRS2 complex acts as a hub for downstream survival signaling, including that involving phosphoinositide 3-kinase (PI3K)-AKT and mitogen-activated protein kinase (MAPK) (15) (16) (17) (18) . FGFR inhibition frequently results in inhibition of MAPK signaling in FGFR1-amplified lung cancer, but without a substantial effect on other pathways, such as PI3K-AKT signaling (19) . We previously reported the presence of co-activated receptor tyrosine kinases (RTKs) in FGFR1-amplified tumors with low FGFR1 protein expression (12) . In this study, we found that alternative RTKs regulated PI3K-AKT signaling even in FGFR inhibitor-sensitive FGFR1-amplified lung cancer. Importantly, activation of these RTKs resulted in the rebound activation of MAPK signaling following FGFR1 inhibition. Incomplete suppression of these key survival signals failed to substantially induce pro-apoptotic proteins, and was associated with intrinsic and acquired resistance to FGFR inhibitors. Our results may help explain the low clinical response rates to FGFR inhibitors in FGFR1-amplified lung cancer.
Materials and methods

Cell lines and reagents
The lung cancer cell lines, NCI-H1581, DMS-114, NCI-H520, NCI-H1703, Calu-3 and NCI-H1993, and a colorectal cancer cell line, HCT-116, were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). HCC95 was obtained from the Korean Cell Line Research Foundation. The human lung embryonic fibroblast line, MRC-5, was obtained from RIKEN Cell Bank. SW620 cells were given by Massachusetts General Hospital. Cells were cultured in RPMI1640 (Invitrogen, Carlsbad, CA, USA) with 5% FBS. All cell lines were tested and authenticated in February 2015 by short tandem repeat analysis with GenePrint 10 System (Promega, Milan, Italy) by the Japanese Cell Research Bank. Cells were regularly screened for Mycoplasma using a MycoAlert Mycoplasma Detection Kit (Lonza, Verviers, Belgium). BGJ398, PD173074, trametinib, linsitinib, crizotinib, JNJ-38877605 and imatinib were obtained from Active Biochem (Hong Kong, China). Lapatinib was purchased from Selleck (Houston, TX, USA). Compounds were dissolved in dimethyl sulfoxide to a final concentration of 10 mmol/l and stored at −20°C.
Establishment of NCI-H1581 cells resistant to FGFR inhibitors
NCI-H1581 cells were seeded at ~70% confluence in 10-cm dishes. PD173074 or BGJ398 was added at a starting concentration of 1 nM, and cells were maintained in fresh drug-containing medium changed every ~72 h. Cells were passaged once they reached confluence. After every two passages at a given drug concentration, the concentration was increased in half-log intervals until a final concentration of 1 μM was achieved. The resulting pools of cells resistant to PD173074 or BGJ398 were maintained with 1 μM of each drug. From BGJ398-resistant cells, 10 clones were established.
Protein analysis
For Western blot analysis, lysates were prepared by using Cell Lysis Buffer (Cell Signaling Technologies, Danvers, MA, USA); the procedures for Western blotting and immunoprecipitation were described previously (20) (21) (22) . Antibodies used in this study are summarized in Supplementary  Table 1 is available at Carcinogenesis Online. Human phospho-RTK arrays were obtained from R&D Systems (Minneapolis, MN, USA) and used according to the manufacturer's instructions. All immunoblots are representative of three independent experiments and RTK array was replicated twice.
Western blot quantification
Western blot images were captured and quantified using Fusion SOLO S (Vilber, Collégien, France).
Growth assay
Assessment of cell viability was performed as follows. Cells were seeded in 96-well plates so that the control cells would reach ~80% confluency at the end of the assay. On the following day, the cells were treated with increasing concentrations of the indicated drugs for 72 h. Treatments with each concentration was performed six times (n = 6). Cell viability was evaluated by using the Cell Counting Kit -8 assay (Dojindo Laboratories, Kumamoto, Japan). Luminescence was recorded by iMark Microplate Reader (Bio-Rad, Hercules, CA, USA). The data were graphically displayed using GraphPad Prism version 6.0 (GraphPad Software).
siRNA knockdown
Cells were seeded into six-well plates at a density of 1-2 × 10 5 cells/well. Twenty-four hours later, cells were transfected with siRNA against plateletderived growth factor receptor-α (PDGFRα) #1 (siGENOME siRNA, Dharmacon), PDGFRα #2 (Silencer Select siRNA, Ambion), GAB1 #1 (Stealth RNAi, Invitogen), GAB1 #2 (siGENOME), insulin receptor substrate 4 (IRS4) #1 (siG-ENOME), IRS4 #2 (Stealth RNAi), ERBB3 #1 (Silencer Select), ERBB3 #2 (Silencer Select), or Stealth RNAi-negative control low GC Duplex #3 (Invitrogen) using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. Transfected cells were cultured at 37°C for 72 h before analysis.
Gene copy number analysis
Genomic DNA was extracted by a DNeasy Blood & Tissue Kit (Qiagen, Velno, Limburg, Netherlands). MET copy number was analyzed using a TaqMan gene copy number assay (ViiA Real-Time PCR System, assay ID: Hs01432482_cn, Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. For the TaqMan Copy Number Reference Assay, human RNase P was used as the endogenous reference gene. Fold increase in copy number was calculated as the ratio of the MET signal in each cell line to the ratio obtained in MRC-5 cells. The NCI-H1993 cell line was used as a positive control for MET amplification.
Quantitative PCR analysis
RNA was extracted using the RNeasy Mini Kit (Qiagen), and cDNA was generated by the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Waltham, MA, USA) according to the manufacturer's instructions. Quantitative real-time PCR was performed using Power SYBR Green PCR Master Mix (Thermo Fisher). Each sample was normalized to the housekeeping gene actin. All samples were analyzed in triplicate, and the relative expression to NCI-H1581 parental cells was determined. Primer sets are MET forward (5′-TGGCATGTCAACATCGCTCT-3′) and MET reverse (5′-GGGGAGTTGCAGATTCAGCT-3′); β-actin forward (5′-TACATGGCTGGGGTGTTGAA-3′) and β-actin reverse (5′-AAGAGAGGC ATCCTCACCCT-3′).
Immunofluorescence
Cells grown on coverslips were fixed in 4% paraformaldehyde for 15 min, followed by treatment with 0.2% Triton X-100 on ice for 20 min. Following blocking with 5% milk, the coverslips were incubated with rabbit monoclonal anti-MET antibody overnight at 4°C. On the next day, the coverslips were nm for 4′,6-diamidino-2-phenylindole were stacked and merged. A total of 8000 4′,6-diamidino-2-phenylindole-positive nuclei were assessed for labeling with MET in parental cells, whereas at least 600 cells were counted for each resistant cell. Immunofluorescence was visually assessed by two independent microscopists to avoid subjective bias in their conclusions.
Abbreviations
FISH analysis
The MET 7q31.2 chromosomal locus was labeled with LSI MET Spectrum Red Probe. Centromere 7 labeled with Spectrum Green Probe (CEP7(D7Z1), Abbott, Abbott Park, IL, USA) was paired to control to determine the MET copy number. FISH was performed using standard methods (12) . Only nuclei with unambiguous CEP7 signals were scored when determining the copy number.
Results
The FGFR inhibitor BGJ398 failed to induce sustained inhibition of MAPK signaling in FGFR1-amplified lung cancer cell lines
In FGFR1-amplified lung cancer cell lines, FGFR inhibition led to the downregulation of MAPK signaling whereas it had a minimal effect on PI3K-AKT signaling (12, 19) . To further assess the effect of FGFR inhibition on MAPK signaling, six FGFR1-amplified lung cancer cell lines were treated with the pan-FGFR inhibitor BGJ398 for both 1 and 24 h. The characteristics of the cell lines used in this study are shown in Supplementary Table 2 is available at Carcinogenesis Online. As expected, FGFR inhibition had a minimal effect on p-AKT ( Figure 1A ). Although 1-h treatment with BGJ398 suppressed phosphorylation of extracellular signalregulated kinase (p-ERK), except in HCC95 cells, we observed the re-accumulation of p-ERK following 24-h treatment with BGJ398. Of note, in the NCI-H1581 cell line, there was no basal AKT activation and there was sustained suppression of p-ERK following BGJ398 treatment ( Figure 1A ). The level of extracellular signal-regulated kinase (ERK) phosphorylation at 24 h appeared to be associated with the sensitivity to the drug ( Figure 1B and C). These results suggest that incomplete suppression of p-ERK may underlie the lack of sensitivity to BGJ398 in FGFR1-amplified lung cancer cells.
Crosstalk between FGFR1 and co-activated RTKs in FGFR1-amplified lung cancer cell lines with low FGFR1 protein expression
To determine the reason for reactivation of MAPK signaling, we first analyzed FGFR1-amplified cell lines with low FGFR1 protein expression (Supplementary Figure 1 is available at Carcinogenesis Online). We previously reported the presence of co-activated RTKs in these cell lines, including HCC95, Calu-3 and NCI-H1703 (12) . In HCC95 cells, the epidermal growth factor receptor (EGFR) family was activated by the overexpression of the ERBB3 ligand, neuregulin 1 (NRG1) (12) . Consistent with this, ERBB3 knockdown downregulated both p-AKT and p-ERK in HCC95 cells ( Figure 2A ). We next evaluated the influence of EGFR/HER2 and FGFR inhibition on the activation of PI3K-AKT and MAPK signaling. Although the EGFR/HER2 inhibitor lapatinib strongly suppressed p-AKT and p-ERK after 6 h of treatment, 24-h treatment resulted in rebound activation of these proteins ( Figure  2B ). Although BGJ398 monotherapy affected neither signal, the combination of lapatinib with BGJ398 negated the reactivation Error bars represent mean ± SD.
of p-AKT and p-ERK induced by long-term lapatinib treatment ( Figure 2B ). Furthermore, FRS2 phosphorylation was downregulated only when BGJ398 and lapatinib were combined. These results suggest the existence of crosstalk between the EGFR family and FGFR1 in the HCC95 cell line. We next analyzed the NCI-H1703 cell line, which is characterized by both FGFR1 and PDGFRα amplification (23, 24) . PDGFRα suppression by knockdown or pharmacological inhibition by imatinib resulted in near complete suppression of p-AKT ( Figure 2C and D) . In contrast, both imatinib and BGJ398 suppressed p-ERK, indicating that MAPK signaling was regulated by both FGFR1 and PDGFRα. Moreover, long-term treatment with either drugs resulted in rebound activation of p-ERK, which was abrogated by combinatorial inhibition of FGFR and PDGFRα ( Figure 2D ). These results suggest the presence of crosstalk between FGFR1 and PDGFRα in NCI-H1703 cells. Notably, in these cells, the inhibition of either FGFR or PDGFRα increased phosphorylation of the other protein ( Figure 2D ). To further analyze the mechanism of the crosstalk between FGFR1 and PDGFRα, FGFR1 was immunoprecipitated in NCI-H1703 cells ( Figure 2E ). We found that FGFR1 bound directly to PDGFRα, suggesting that crosstalk was mediated by heterodimerization of FGFR1 with PDGFRα. Collectively, these results indicate that ERK signaling is regulated by both FGFR1 and alternative RTKs in FGFR1-amplified lung cancer cell lines with low protein expression.
Crosstalk between FGFR and insulin-like growth factor 1 receptor (IGFR) hindered the complete suppression of MAPK signaling by FGFR inhibition in the DMS-114 cell line
Although DMS-114 cells were sensitive to BGJ398 and demonstrated high expression of the FGFR1 protein, long-term FGFR inhibition resulted in the reactivation of p-ERK ( Figure 1A) . The results in FGFR1-amplified cells with low expression of FGFR1 protein led us to test the existence of crosstalk between FGFR1 and alternative RTKs in the DMS-114 cell line. Because PI3K-AKT signaling was dominantly regulated by alternative RTKs in cells with low FGFR1 expression, we sought to determine which RTKs regulated this signaling in DMS-114 cells. Immunoprecipitation of the PI3 kinase regulatory subunit (p85) identified a 160-kD protein bound to p85. On the basis of its molecular weight, we hypothesized that this band represented a member of the insulin receptor substrate (IRS) family of proteins. Indeed, we confirmed that one such protein, IRS4, immunoprecipitated with p85 in DMS-114 cell lines ( Figure 3A) . IRS4 knockdown consistently achieved near-complete inhibition of p-AKT ( Figure 3B ). Moreover, as was the case in cells with low FGFR1 expression, IRS4 knockdown downregulated p-ERK in DMS-114 cells. ERK phosphorylation was downregulated by both IRS4 knockdown and BGJ398 treatment, suggesting that ERK signaling was maintained by both IGFR-IRS4 and FGFR. Indeed, the combination of IRS4 knockdown and BGJ398 treatment led to further inhibition of p-ERK ( Figure 3B ). The involvement of FGFR and IGFR in the activation of ERK signaling was confirmed by treatment with BGJ398 and an IGFR inhibitor, linsitinib, which resulted in near-complete suppression of p-ERK in DMS-114 cells ( Figure  3C ). However, in contrast to IRS4 knockdown, linsitinib did not completely inhibit p-AKT in DMS-114 cells. Although BGJ398 monotherapy had modest effects on AKT phosphorylation, the addition of BGJ398 to linsitinib resulted in further inhibition of p-AKT. These results suggest that FGFR1 activates AKT phosphorylation through IRS4 when the IGFR-IRS4 signal is inhibited. Consistent with this, FGFR1 signaling was previously shown to upregulate IRS4 phosphorylation (25) .
We next determined whether crosstalk between FGFR1 and IGFR affected cell growth and apoptosis. Upregulation of both pro-apoptotic proteins PUMA and BIM was shown to be required for oncogene inactivation-induced apoptosis (26) . Although BIM is downstream of MAPK signaling, PUMA is a central apoptotic effector that is induced by the inhibition of PI3K-AKT signaling. Inhibition with BGJ398 and linsitinib induced the pro-apoptotic protein BIM by suppressing ERK phosphorylation, but only the combination of these inhibitors resulted in complete suppression of ERK phosphorylation and robust BIM upregulation ( Figure 3D) . Similarly, the combination of BGJ398 with linsitinib was needed to suppress AKT phosphorylation and induce PUMA expression, whereas these effects were modest with each agent alone. Finally, the combination of BGJ398 with linsitinib achieved better induction of apoptosis than either inhibitor alone, as determined by poly (ADP ribose) polymerase cleavage ( Figure 3D ) and growth suppression ( Figure 3E ) in DMS-114 cells. Taken together, these results suggest that the FGFR inhibitor could not fully induce pro-apoptotic proteins and growth inhibition because of crosstalk mediated by an alternative RTK, even in the FGFR inhibitor-sensitive DMS-114 cell line. 
Signal crosstalk through GAB1 leads to acquired resistance to an FGFR inhibitor in the NCI-H1581 cell line
The NCI-H1581 cell line showed the greatest sensitivity to the FGFR inhibitor BGJ398 among the examined FGFR1-amplified lung cancer cell lines ( Figure 1C ). Although FGFR inhibition induced sustained suppression of p-ERK in NCI-H1581 cells, it is possible that these cells' sensitivity to BGJ398 was due to their lack of AKT phosphorylation. We hypothesized that incomplete suppression of p-ERK or AKT activation could have led to acquired resistance to FGFR inhibitors in the NCI-H1581 cell line. To test this theory, cells resistant to the FGFR inhibitor PD173074 (NCI-H1581 PDR) were generated from the NCI-H1581 cell line ( Figure 4A ). Indeed, Western blot analysis showed that PD173074 could not induce complete suppression of p-ERK in resistant cells. In addition, AKT phosphorylation occurred in NCI-H1581 PDR cells ( Figure 4B ). To determine the reason for p-AKT positivity, we performed immunoprecipitation of p85. We identified a 110-kD protein bound to p85 in NCI-H1581 PDR cells, whereas the association was not observed in parental cells ( Figure 4C ). The molecular weight suggested that GAB1 was the phosphoprotein that coimmunoprecipitated with p85. Indeed, GAB1 knockdown decreased the interaction between the phosphoprotein and p85 ( Figure 4D ). We next assessed whether GAB1 also affected MAPK signaling. Importantly, GAB1 knockdown resulted in downregulation of p-ERK. Furthermore, the combination of FGFR inhibition with GAB1 knockdown achieved complete suppression of ERK phosphorylation ( Figure 4E ). These results suggest that GAB1-mediated activation of PI3K-AKT and MAPK signaling caused resistance to an FGFR inhibitor in the NCI-H1581-PDR cell line. Lysates from these cells were immunoprecipitated and blotted as in C. Notably, the band that was detected by phosphotyrosine antibody in scramble siRNA-transfected cells disappeared following GAB1 knockdown. (E) Both GAB1 and FGFR1 activate ERK signaling while GAB1 dominantly regulates AKT signaling in NCI-H1581-PDR cells.
NCI-H1581-PDR cells were transfected with two different siRNAs targeting GAB1 or scramble siRNA and cultured for 48 h. Then, old media was replaced with media with or without 1 μM PD173074, and cells were treated for an additional 24 h. Lysates were probed with the indicated antibodies.
MET activated AKT and ERK signaling through GAB1 in NCI-H1581 FGFR inhibitor-resistant cells.
We next investigated whether any RTKs activated GAB1 in NCI-H1581 PDR cells. A phospho-RTK array comparing parental and PD173074-resistant cells identified MET activation in resistant cells ( Figure 5A ). Although MET expression was gradually upregulated by stepwise increases in drug concentration, cells resistant to 100 nM PD173074 already exhibited ERK phosphorylation in the presence of PD173074 ( Figure 5B) , and also showed similar AKT activation levels as 1-µM resistant cells. Immunoprecipitation of p85 demonstrated that the p85/GAB1 complex was dissociated by a MET inhibitor, JNJ-38877605, not by PD173074, indicating that GAB1 was phosphorylated in association with activated MET ( Figure 5C ). We confirmed these results by developing NCI-H1581 cells that were resistant to another FGFR inhibitor, BGJ398. As with the PD173074-resistant cells, clones of BGJ398-resistant NCI-H1581 cells (NCI-H1581-BGR) demonstrated upregulated MET protein expression and AKT phosphorylation (Supplementary Figure 2A -C 1 is available at Carcinogenesis Online). These resistant clones were sensitive to the combination of BGJ398 and MET inhibitors, such as crizotinib and JNJ-38877605 ( Figure 5D and Supplementary Figure 3A is available at Carcinogenesis Online). Western blot analysis showed that AKT activation depended on MET ( Figure 5E and Supplementary Figure 3B is available at Carcinogenesis Online). In contrast, both FGFR and MET played roles in the activation of ERK signaling. Interestingly, although p-FRS2 was not inhibited by BGJ398 alone, it was inhibited by the combination of BGJ398 and MET inhibitors, suggesting the presence of crosstalk between MET-GAB1 and FRS2. Furthermore, BIM and PUMA were upregulated only when cells were treated with the combination of BGJ398 and MET inhibitors, indicating that oncogene-induced signaling was regulated by both FGFR1 and MET via crosstalk in resistant cells ( Figure 5F and Supplementary Figure 3C is available at Carcinogenesis Online).
Pre-existence of MET-expressing clones in NCI-H1581 parental cells
Finally, we investigated how MET expression was induced in FGFR inhibitor-resistant cells. It is known that EGFR-TKI resistance arises as a result of focal amplification of the MET gene (27) . To determine whether gene amplification underlies the elevated protein level of MET in NCI-H1581-BGR cells, we performed gene copy number analysis using FISH and quantitative PCR. However, the number of MET gene copies per cell was not shown to be elevated by either FISH (Figure 6A and Supplementary  Table 3 is available at Carcinogenesis Online) or quantitative PCR ( Figure 6B ). In contrast to the lack of evidence of gene amplification, upregulation of MET mRNA and protein expression was observed in cells resistant to a very low concentration (3 nM) of BGJ398 ( Figure 6C and D) . Moreover, we detected MET mRNA even in NCI-H1581 parental cells ( Figure 6C ). These results led us to evaluate the existence of MET-expressing clones in parental cells. Indeed, ~0.3% parental cells were positive for MET expression ( Figure 6E and F) . Of note, no cells demonstrated positive staining for control immunoglobulin G. Together, these results indicate that a subpopulation of MET-expressing cells preexisted in NCI-H1581 parental cells.
Discussion
FGFR1 gene amplification has been identified frequently in nonsmall-cell lung cancer; however, early clinical trials of FGFR inhibitors were disappointing, and activity against these tumors was modest at best. In this study, we showed that the activation of alternative RTKs reduced the efficacy of FGFR inhibitors in FGFR1-amplified lung cancer. These RTKs dominantly activated PI3K-AKT signaling and also mitigated the sustained inhibition of MAPK signaling following FGFR inhibitor treatment. Incomplete suppression of these key survival signals failed to substantially induce pro-apoptotic proteins, leading to intrinsic and acquired resistance to FGFR inhibitors.
Crosstalk mediated by FGFR is a well-known cause of resistance to RTK inhibitors in oncogene-addicted cancers (28) (29) (30) (31) . Conversely, ligand-mediated activation of alternative RTKs, such as EGFR family proteins and MET, was associated with resistance to FGFR inhibitors in FGFR2-amplified and FGFR3-translocated cells (31) . In FGFR1-amplified lung cancer, alternative RTKs dominantly activate PI3K-AKT and also mitigate sustained MAPK inhibition following FGFR inhibition. We previously reported the roles of co-activated RTKs in activating PI3K-AKT signaling in FGFR1-amplified lung cancers with low FGFR1 protein expression, suggesting that co-activation of alternative RTKs was needed to reinforce the limited activation of survival signaling by low expression of FGFR1 (12) . However, the current study indicates that alternative RTKs play a widespread role in survival signaling in FGFR1-amplified lung cancer, regardless of FGFR1 protein expression, raising the question of whether FGFR1 amplification induces oncogene addiction in lung cancer.
In FGFR inhibitor-sensitive NCI-H1581 cells, FGFR was the only activated RTK and resulted in a lack of AKT activation and full FGFR dependence in terms of MAPK activation. These results suggest that FGFR dependency and sensitivity to FGFR inhibitors can be assessed by measuring AKT activation. Consistent with this, AKT activation was shown to mediate acquired resistance to BGJ398 in cells with aberrant FGFR signaling (32) . However, the relationship between AKT activation and sensitivity to FGFR inhibitors should be assessed in patients enrolled in clinical trials. Furthermore, the exact roles of PI3K-AKT signaling in growth and survival must still be elucidated in tumors with aberrant FGFR. When oncogene-addicted cancers are sensitive to TKIs, the TKIs usually lead to downregulation of critical survival signaling pathways, including those of PI3K-AKT and MAPK (33) . Indeed, in FGFR inhibitor-sensitive FGFR2-amplified gastric cancer cells, FGFR2 mediated the transactivation of RTKs, bringing PI3K/mTOR signaling under FGFR2 control (19) . However, despite promising results in a clinical trial of BGJ398, FGFR inhibitors led to only marginal downregulation of p-AKT in FGFR3 mutant urothelial cancer cell lines and FGFR2/3 translocated cancer cell lines (19, 31, 34) . These results indicate that signaling sufficient to drive addiction to aberrant FGFR depends on cellular context.
In FGFR1-amplified lung cancer, alternative RTKs mediate their signal through adaptor proteins and interruption of sustained MAPK suppression. Reactivation of MAPK signaling was shown to result in intrinsic resistance to target therapies (22, 33, 35) . Moreover, the oncogenes in oncogene-addicted cancer cells regulate a number of survival signaling pathways, and recent studies indicated that those involving MAPK were critical for the maintenance of cell survival (36, 37) . These results suggest that crosstalk between alternative RTKs and FGFR1 in MAPK signaling may mitigate the efficacy of BGJ398 administered with a PI3K inhibitor, a combination currently under evaluation in a phase Ib trial in lung cancers (NCT01928459). Combinatorial inhibition of FGFR1 and each alternative RTK might be effective against FGFR1-amplified lung cancer. However, our results indicate that several kinds of RTKs may be involved, which makes it difficult to predict the appropriate combinatorial strategy in each lung cancer patient harboring FGFR1 amplification.
In this study, MET-expressing clones were already detectable at a very low frequency even before FGFR inhibitor resistance was induced in NCI-H1581 cells. Although we did not observe MET amplification in our clones, it was previously shown to induce FGFR inhibitor resistance in NCI-H1581 (38) . Interestingly, MET signaling was mediated differently in the pre-existing METexpressing clones and the MET-amplified clones: GAB1 in the former and ERBB3 in the latter. These results indicate polyclonal evolution of drug resistance with the same outcome. The report also identified another resistant clone expressing MET protein without gene amplification, although the mechanism was not elucidated (38) . A recent report also identified a METoverexpressing subpopulation in BGJ398-resistant DMS-114 cells (6) , supporting the importance of MET in the resistance mechanism to FGFR inhibitors.
In conclusion, our study showed that key oncogene signaling pathways frequently involved alternative RTKs in FGFR1-amplified lung cancer. These alternative RTKs dominantly activated PI3K-AKT signaling and also mitigated the sustained inhibition of MAPK signaling by FGFR inhibitors. These results suggest that FGFR inhibitor monotherapy is not likely to be effective in unselected populations. The lack of AKT activation or reduced AKT activation might be associated with less involvement of alternative RTKs and better sensitivity to FGFR inhibition. Therefore, it may be worth assessing this relationship in current clinical trials.
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